Liver cancer has a high incidence rate in China and is very harmful, which is the key point and difficult point in China’s medical and health services. There are three main reasons for the difficulty of liver cancer: firstly, the prevention measures of liver cancer in China are not yet perfect and systematic; secondly, the awareness of early diagnosis is not yet popular, resulting in the late diagnosis of liver cancer in China; thirdly, the treatment mode of liver cancer is still inadequate in terms of human culture, individualization and scientificization. Sun Wenbing, Department of Hepatobiliary, Pancreatic and Splenic Surgery, West Hospital of Beijing Chaoyang Hospital, Capital Medical University, said that the key to solving the difficulty of liver cancer is to recognize the three “most important” aspects of liver cancer. First, liver cancer is almost the most preventable cancer. Most liver cancers occur in patients with chronic viral hepatitis, and preventing the spread of viral hepatitis B or C is the most effective measure to prevent liver cancer. The main transmission routes of viral hepatitis B or C are mother-to-child transmission and blood transmission. Cutting off these two transmission routes is actually not difficult, but requires systematic and systemic efforts. Second, liver cancer is almost the easiest cancer to diagnose early. It is well known that 70%-80% of liver cancer patients have significantly elevated fetoprotein in their blood, and for liver cancer with no elevated fetoprotein, ultrasound examination also has high sensitivity. Therefore, if people with high risk of liver cancer can regularly test fetoprotein in their blood and do ultrasound examination, most of liver cancers can be diagnosed at an early stage. Thirdly, liver cancer is almost the most curable cancer through minimally invasive treatment. The liver is only “walled off” from the outside world and is a semi-exposed organ, which lays the anatomical foundation for ablative treatment of hepatocellular carcinoma through a percutaneous puncture route. Local ablation therapy for hepatocellular carcinoma has been developed for nearly 30 years, and radiofrequency ablation therapy has become one of the three major curative tools along with hepatectomy and liver transplantation. Studies have shown that for small hepatocellular carcinoma with diameter ≤ 3.0 cm, the five-year survival rate should be more than 80% for those who apply percutaneous radiofrequency ablation therapy, especially for standardized and repeated applications. Knowing where the “most” hepatocellular carcinoma is, we know the direction we should strive for.